Krebs Biochemicals and Industries Limited (NSE: KREBSBIO) informed the exchange on June 26, 2026, at 13:17 IST that its Board of Directors had convened and disclosed the outcome of their meeting, as per a regulatory filing submitted to the National Stock Exchange of India.
Board Meeting Disclosure
The company filed an "Outcome of Board Meeting" announcement on NSE on June 26, 2026. The filing, categorised under standard corporate governance disclosure norms, did not contain elaborated specifics in the exchange attachment text beyond confirming the board meeting had taken place. No dividend declaration was included as part of this announcement.
Dividend History: A Two-Decade Gap
A review of KREBSBIO's available dividend history on NSE reveals a strikingly sparse record. The company's last documented dividend was announced on June 9, 2005, when the Board of Directors recommended a dividend of ₹3.00 per share for the financial year 2004-05, representing a payout rate of 30% of face value. There is no subsequent dividend announcement on record for the company across the intervening period spanning more than two decades.
- Last dividend declared: ₹3.00 per share (FY 2004-05)
- Dividend type: Final dividend
- Payout percentage: 30% on face value
- Years since last dividend: Approximately 21 years
Market Data Limitations
As of the time of this filing, live quote data and trade information for KREBSBIO were not available through the exchange data feed. Consequently, a current dividend yield calculation, delivery percentage analysis, and 52-week high-low range context cannot be presented with verified figures at this time. Investors are advised to refer directly to the NSE trading platform for the latest price data for KREBSBIO (ISIN: INE268B01013).
Company Background
Krebs Biochemicals and Industries Limited is an NSE-listed entity operating in the biochemicals and industrial chemicals segment. The company has maintained its listing on the exchange for over two decades. Its ISIN is INE268B01013. The absence of dividend distributions over an extended period is a notable characteristic of the stock's return profile for income-focused investors.
What This Means for Investors
The board meeting outcome filing is a mandatory regulatory disclosure under SEBI's Listing Obligations and Disclosure Requirements (LODR) regulations. Investors tracking KREBSBIO should note the following points arising from available data:
- No dividend has been declared by the company since FY 2004-05, making the current dividend yield effectively nil based on historical payout records.
- The absence of live trade data limits real-time assessment of valuation metrics such as price-to-earnings ratio relative to the sector PE.
- The board meeting on June 26, 2026, did not result in any announced shareholder distribution, continuing the long-standing pattern of no dividend payouts.
- Investors with income generation objectives should factor in the company's 21-year dividend hiatus when evaluating the stock.
The complete text of the board meeting outcome, once made fully available on the NSE filing portal, will provide further clarity on decisions taken during the June 26 meeting. Investors are encouraged to review the detailed filing on the NSE EDGAR platform under the KREBSBIO symbol for complete disclosures.